42 results
Page 2 of 3
8-K
EX-99.1
kyct9p
5 Nov 19
Top-line data from PROTECTOR 1 study expected by early first quarter of 2020
8:00am
8-K
EX-99.1
1o42b3
14 Aug 19
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
fp33 gi122hg7nr
23 Jul 19
Other Events
8:05am
8-K
EX-99.1
gzh9e
15 May 19
Results of Operations and Financial Condition
9:00am
8-K
EX-99.1
q6suttm8350i42viu0
9 May 19
Other Events
8:10am
424B5
vx1dk1
20 Mar 19
Prospectus supplement for primary offering
5:13pm
424B5
tctoo6chz9v7vt9x
18 Mar 19
Prospectus supplement for primary offering
4:25pm
8-K
EX-99.1
qxetu81ezi9ruq82
18 Mar 19
Positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA); Phase 3 program of RTB101 expected to initiate in 2Q19
4:02pm
8-K
EX-99.2
cmfrxp6w m9cm4hlan8
18 Mar 19
Regulation FD Disclosure
7:21am
8-K
EX-99.1
65nb9ic 2mcw94wx
18 Mar 19
Regulation FD Disclosure
7:21am
8-K
EX-99.1
h7a3pz
7 Feb 19
Regulation FD Disclosure
8:01am
8-K
EX-99.2
g1nawzs
7 Feb 19
Regulation FD Disclosure
8:01am
S-3
py0kvxl9 g181hqb5q
1 Feb 19
Shelf registration
5:31pm
8-K
EX-99.1
d8o8yh7qqip30 4yjf
7 Jan 19
Regulation FD Disclosure
8:00am
8-K
EX-99.2
lvrdc
16 Oct 18
Regulation FD Disclosure
7:20am
8-K
EX-99.1
ky2kow37ub
16 Oct 18
Regulation FD Disclosure
7:20am
8-K
EX-99.2
zr43vnfd30oni3ypf
25 Jul 18
Regulation FD Disclosure
8:30am